Business
Posting of Annual Report and Notice of AGMm
Arecor Therapeutics plc has published its Annual Report and Accounts for the year ended 31 December 2025 and issued a Notice of its Annual General Meeting, scheduled for 28 May. Shareholders will be able to view the AGM proceedings online via the Investor Meet Company platform, though voting must be submitted by proxy as online voting is not available. The full report and notice are also accessible on the company's website. Disclaimer*
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\n \nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nPosting of Annual Report and Notice of AGM\nCambridge, UK, 28 April 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, has today published and posted to shareholders its Annual Report and Accounts for the year ended 31 December 2025.\nThe Company has also shared the Notice of the Annual General Meeting (\"AGM\") which will be held on Thursday, 28 May at 9.30am BST at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ.\nIn order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform.\nPlease note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible. Shareholders that wish to attend the AGM remotely should register for the event in advance by emailing [email protected]\nThe Annual Report and Accounts and Notice of AGM are also now available to view and download from the Company's website at https://arecor.com/investor-centre/shareholder-information/\n-ENDS-\nFor more information, please contact:\n\n\n\n\nArecor Therapeutics plc \nDr Sarah Howell, Chief Executive Officer\nDavid Ellam, Chief Financial Officer\n\n\n \n+44 (0) 1223 426060\[email protected]\n\n\n\n\nSinger Capital Markets Advisory LLP\n(NOMAD and Broker) Phil Davies, James Fischer\n\n\n \n+44 (0) 20 7496 3000\n\n\n\n\nVigo Consulting (Financial Communications) Melanie Toyne-Sewell, Rozi Morris\n\n\n+44 (0) 20 7390 0230\[email protected]\n\n\n\n\nVida Strategic Partners (US Investor Relations)\nStephanie Diaz\n\n\n+1 (415) 675-7401\[email protected]\n\n\n\n\n \nNotes to Editors\nAbout Arecor\nArecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.\nLead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in de...